Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Overview of Oncocyte Corporation
Oncocyte Corporation (OCX) is a diagnostics technology company specializing in the discovery, development, and commercialization of advanced non-invasive diagnostic tests. Utilizing liquid biopsy techniques, Oncocyte is dedicated to improving clinical decision-making by enabling early and precise detection of cancer as well as monitoring transplant health. The company's innovative approach is built on proprietary biomarkers that allow differentiation between benign and malignant conditions, offering a disruptive solution in areas where conventional diagnostic methods are often ambiguous, invasive, or costly.
Core Business Areas and Technologies
At the heart of Oncocyte's business is its commitment to advancing molecular diagnostics through:
- Liquid Biopsy Diagnostics: Employing blood or urine samples, these non-invasive tests are designed to detect cancers such as lung, breast, and bladder by analyzing genetic markers and gene expression profiles.
- Transplant Monitoring: The company has developed sophisticated assays for monitoring organ transplant patients. For instance, VitaGraft Kidney leverages donor-derived cell-free DNA (dd-cfDNA) to detect early signs of graft injury or rejection, thereby providing actionable clinical insights.
- Advanced Molecular and Genetic Assays: Oncocyte's pipeline includes tests such as GraftAssure for research purposes and DetermaIO and DetermaCNI which assess the tumor microenvironment and copy number instability respectively, supporting therapeutic decision-making in oncology.
Scientific Approach and Industry Position
Oncocyte integrates state-of-the-art digital PCR technology and gene expression analysis to ensure high sensitivity, rapid turnaround times, and user-friendly workflows. This scientific rigor has established dd-cfDNA as a trusted biomarker in both oncology and transplant medicine. By addressing significant unmet clinical needs, such as reducing the time to diagnose antibody-mediated rejection in kidney transplants, Oncocyte positions itself as a key technology innovator within the broader molecular diagnostics industry.
Market Significance and Strategic Collaborations
The company has successfully carved out a niche in a competitive landscape by focusing its efforts on areas where diagnostic ambiguities and the invasiveness of current testing methods impact patient care. Its strategic partnerships with high-caliber industry players, including collaborations with research centers and established diagnostic firms, bolster its market presence. This collaborative strategy not only validates Oncocyte’s technology but also facilitates the land-and-expand approach needed to build a robust network of clinical adoption.
Operational Excellence and User-Centric Solutions
Oncocyte’s diagnostic tests are developed with an emphasis on scalability, cost-effectiveness, and ease of integration into existing clinical workflows. By delivering fast, reliable, and non-invasive testing options, the company helps physicians and health care providers make more informed decisions. This operational excellence reinforces the company’s reputation for combining innovative science with practical clinical utility, ensuring that both research and patient outcomes benefit from its technologies.
Research, Development, and Clinical Applications
Underpinned by over a decade of dedicated research into molecular biomarkers, Oncocyte continuously refines its product offerings to meet evolving clinical needs. The company’s broad R&D pipeline not only spans the detection and monitoring of cancer but also encompasses organ transplant applications that support early intervention. Its scientifically sound approach is corroborated by peer-reviewed publications and clinical studies, underscoring the potential of its assays to revolutionize diagnostic practices.
Conclusion
Oncocyte Corporation exemplifies the convergence of pioneering science, advanced diagnostic technology, and strategic market positioning in the field of molecular diagnostics. By offering breakthrough solutions that emphasize non-invasive testing and rapid clinical insights, the company stands as a robust resource for physicians, researchers, and healthcare providers. Its commitment to quality, scientific integrity, and practical application assures stakeholders of its capability to deliver reliable diagnostic outcomes across both oncology and transplant medicine.
Oncocyte (Nasdaq: OCX), a diagnostics technology company, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025. CEO Josh Riggs and CFO Andrea James will represent the company, with Riggs scheduled for a fireside chat on April 7, 2025, at 3:45 PM ET.
During the conference, the executives will discuss Oncocyte's innovative diagnostic technologies and highlight their progress in commercializing a regulated organ transplant rejection monitoring test kit. The company is pursuing a market-disruptive approach to lead in transplant monitoring solutions.
Investors interested in attending the virtual fireside chat or scheduling one-on-one meetings should contact their Needham sales representative.
Oncocyte (OCX) reported Q4 2024 revenue of $1.5 million and full-year revenue of $1.9 million, primarily from pharma services. The company achieved several key milestones in 2024:
- Launched GraftAssure RUO assay in July 2024
- Secured Bio-Rad Laboratories as strategic partner and investor (9.66% ownership)
- Raised $57 million in equity funding
- Expanded Medicare coverage for VitaGraft Kidney test
- Had successful FDA pre-submission meeting in December 2024
The company is developing a regulated organ transplant rejection monitoring test kit targeting a $1 billion addressable market. They aim for FDA submission by end of 2025 and authorization in 2026. Q4 2024 showed $595,000 gross profit (40% margin) and operating expenses of $34.2 million, including $41.9 million in non-cash impairment losses offset by $13.7 million non-cash gain from contingent consideration.
Oncocyte (Nasdaq: OCX), a diagnostics technology company, has scheduled its fourth quarter 2024 financial results announcement for March 24, 2025, after market close. The company will host a live Zoom webinar at 2:00 p.m. PT on the same day to discuss the results, followed by a Q&A session. Investors can access the webinar through registration, and a replay will be available on Oncocyte's investor relations website.
Oncocyte Corp (Nasdaq: OCX) has announced its participation in BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking place on February 11-12, 2025, in Snowbird, Utah. CEO Josh Riggs and CFO Andrea James will represent the diagnostics technology company at the event, where they will conduct one-on-one meetings with potential investors.
Interested investors attending the conference are encouraged to contact BTIG directly to schedule meetings with Oncocyte's leadership team.
Oncocyte Corp. (OCX) has secured $29.1 million through a registered direct offering and concurrent private placement priced at $2.05 per share. The funding round was led by the company's five largest shareholders, including strategic partner Bio-Rad Laboratories, who also committed additional support for clinical trials and commercialization.
The proceeds, combined with current cash, will fully fund the development of Oncocyte's FDA In-Vitro Diagnostic (IVD) transplant assay program. The company's proprietary technology can detect kidney transplant rejection signs over 11 months earlier than standard protocols. The offering includes 3,609,755 shares in the registered direct offering and 7,536,708 shares plus pre-funded warrants for 3,069,925 shares in the PIPE offering.
The transaction is expected to close on February 10, 2025, with Needham & Company acting as financial advisor. The company aims to capture share in the $1 billion global transplant testing market.
Oncocyte Corp (NASDAQ: OCX) has appointed Dr. Paul Billings as Consulting Chief Medical Officer in a part-time role. Dr. Billings, a renowned diagnostics specialist with over 40 years of experience, will support strategic and clinical goals for the company.
Dr. Billings previously served as CEO and Chairman at Biological Dynamics, focusing on exosome-based diagnostics for early cancer detection, and as Chief Medical Officer at Natera during key commercialization phases. He has held advisory and leadership positions at major companies including LabCorp, Quest Diagnostics, and Thermo Fisher Scientific.
Holding M.D. and Ph.D. degrees in immunology from Harvard University, Dr. Billings is board certified in internal medicine and medical genetics. He has held academic positions at Harvard, Stanford, and UC San Francisco, and served on Advisory Boards at the FDA and HHS.
Oncocyte (NASDAQ: OCX) announced expanded Medicare coverage for its VitaGraft Kidney diagnostic test, now including monitoring of patients with newly developed donor-specific antibodies (dnDSA+) for antibody-mediated rejection (AMR). The expansion follows a study showing VitaGraft can detect AMR up to 11 months earlier than standard care.
The coverage was confirmed under MolDX's Local Coverage Determination (LCD) and includes two Z-codes for improved accessibility. This expansion targets a significant market, as up to 20% of patients develop detectable DSA within five years post kidney transplant, representing over 10,000 patients annually in the US. Notably, 24% of patients with dnDSA lose their allograft within 3 years, compared to a 96% five-year survival rate for patients without DSA.
The company aims to commercialize its proprietary diagnostic technology that enables local laboratories to run kitted tests measuring donor-derived cell-free DNA (dd-cfDNA), offering a more affordable and faster alternative to current methods.
Oncocyte Corp (Nasdaq: OCX), a diagnostics technology company, has announced its participation in 'J.P. Morgan Week' alongside the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025.
CEO Josh Riggs and CFO Andrea James will be available for one-on-one meetings with investors during the event. Interested investors can schedule meetings through Julie Silber at PCG Advisory.
Oncocyte Corp. (OCX) announced favorable data for its DetermaCNI™ assay in diagnosing brain tumors through liquid biopsy. Published in Acta Neuropathologica Communications, the study showed the assay's ability to measure somatic copy number aberrations (SCNAs) in cerebrospinal fluid for diagnosing central nervous system tumors.
The study detected SCNAs in 10 out of 12 patients with confirmed central nervous system cancers, while showing no SCNAs in 11 patients with benign lesions. This technology could benefit nearly 300,000 U.S. patients annually who face primary brain tumors or brain metastasis, representing a potential $300 million U.S. market opportunity. The method could provide a less invasive alternative to current brain tissue biopsies.
Oncocyte announced favorable data for its VitaGraft Kidney diagnostic assay, published in Nephrology Dialysis Transplantation. The study demonstrates the test can detect antibody-mediated rejection (AMR) in kidney transplant recipients approximately 11 months earlier than standard protocols. Using donor-derived cell-free DNA (dd-cfDNA) testing, VitaGraft diagnosed AMR in a median of 2.8 months compared to 14.5 months with standard care in patients with donor-specific antibodies. This marks the first randomized interventional study validating dd-cfDNA as a rule-in test for biopsy in high-risk populations.